These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36266091)

  • 1. Statistical power and sample size calculations for time-to-event analysis.
    Zurakowski D; Staffa SJ
    J Thorac Cardiovasc Surg; 2023 Dec; 166(6):1542-1547.e1. PubMed ID: 36266091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical power and sample size calculations: A primer for pediatric surgeons.
    Staffa SJ; Zurakowski D
    J Pediatr Surg; 2020 Jul; 55(7):1173-1179. PubMed ID: 31155391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size calculations in human electrophysiology (EEG and ERP) studies: A systematic review and recommendations for increased rigor.
    Larson MJ; Carbine KA
    Int J Psychophysiol; 2017 Jan; 111():33-41. PubMed ID: 27373837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Power and sample size calculation for log-rank test with a time lag in treatment effect.
    Zhang D; Quan H
    Stat Med; 2009 Feb; 28(5):864-79. PubMed ID: 19152230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
    Jachno K; Heritier S; Wolfe R
    BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
    Tang Y
    Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation.
    Quartagno M; Walker AS; Babiker AG; Turner RM; Parmar MKB; Copas A; White IR
    Trials; 2020 Feb; 21(1):145. PubMed ID: 32029000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Learning Methodological Lessons from Exemplar Studies in Nephrology: PEXIVAS and Sample Size Calculation.
    Sandys V; Sexton DJ
    Kidney360; 2022 Aug; 3(8):1427-1430. PubMed ID: 36176647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sizing clinical trials when comparing bivariate time-to-event outcomes.
    Sugimoto T; Hamasaki T; Evans SR; Sozu T
    Stat Med; 2017 Apr; 36(9):1363-1382. PubMed ID: 28120524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size and statistical power of randomised, controlled trials in orthopaedics.
    Freedman KB; Back S; Bernstein J
    J Bone Joint Surg Br; 2001 Apr; 83(3):397-402. PubMed ID: 11341427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical power and estimation of the number of required subjects for a study based on the t-test: a surgeon's primer.
    Livingston EH; Cassidy L
    J Surg Res; 2005 Jun; 126(2):149-59. PubMed ID: 15919413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consultants' forum: should post hoc sample size calculations be done?
    Walters SJ
    Pharm Stat; 2009; 8(2):163-9. PubMed ID: 18416448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of the value of imaging in enhancing the wellness of your heart (VIEW) trial and the impact of uncertainty on power.
    Ambrosius WT; Polonsky TS; Greenland P; Goff DC; Perdue LH; Fortmann SP; Margolis KL; Pajewski NM
    Clin Trials; 2012 Apr; 9(2):232-46. PubMed ID: 22333998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
    Bedard PL; Krzyzanowska MK; Pintilie M; Tannock IF
    J Clin Oncol; 2007 Aug; 25(23):3482-7. PubMed ID: 17687153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biostatistics for gastroenterologists. Part II ̶ Rethinking sample size.
    Stallings E
    Rev Esp Enferm Dig; 2023 Aug; 115(8):411-413. PubMed ID: 37366033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SurvivalGWAS_Power: a user friendly tool for power calculations in pharmacogenetic studies with "time to event" outcomes.
    Syed H; Jorgensen AL; Morris AP
    BMC Bioinformatics; 2016 Dec; 17(1):523. PubMed ID: 27931206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.